CoChat

Light therapy in medicine: where do we stand?

Open access
Oyama, Yoshimasa, Witowski, Andrea, Adamzik, Michael, Bartels, Karsten, de la Garza Eckle, Tobias · 2026 · Annals of Translational Medicine

The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index; none of the 204 sources its claims cite is checked for support yet.

Abstract

Light therapy encompasses a broad spectrum of interventions, ranging from established clinical applications to emerging and experimental indications. This review evaluates the current state of light therapy across medical disciplines, emphasizing the need to distinguish validated clinical uses, exploratory findings, and preclinical research. The biological effects of light therapy are diverse, with mechanisms depending on wavelength, route of delivery, and biological target. Ocular exposure to bright light primarily acts through the circadian system to influence mood and sleep, whereas peripheral photobiomodulation (PBM) and ultraviolet (UV) phototherapy act directly on local tissues to promote healing. Mitochondrial activation is a proposed general mechanism, but its centrality is likely modality- and context-dependent. Robust clinical evidence supports bright light therapy for seasonal affective disorder (SAD) and UV-B for psoriasis, while moderate evidence exists for dermatological and sleep applications. For delirium, bright light therapy has shown promise in small-scale studies, but large-scale confirmatory clinical trials are still lacking. Other reported uses, including pain management, ischemia-reperfusion (IR) injury, clotting disorders, and infectious lung injury, are largely supported by preclinical and mechanistic studies, particularly those involving intense light that elicits the circadian core protein Period 2 (PER2). The clinical relevance of these mechanisms remains under investigation. Overall, light therapy remains safe when used according to established protocols. This review aims to provide a nuanced synthesis of the field, highlighting both the promise and the limitations of light therapy and emphasizing the importance of the evidence hierarchy in guiding clinical translation and research priorities.

Overview

CoChat Summary

## TL;DR

This review argues that “light therapy” is not one thing but several biologically distinct interventions, with strong evidence for some uses (notably SAD and neonatal phototherapy) and mostly preliminary or preclinical evidence for others. It emphasizes that timing, wavelength, dose, and route of delivery matter, and that many promising organ-protection findings hinge on circadian mechanisms, especially PER2.

## Key findings

  • For seasonal affective disorder (SAD), intense light therapy is reported as highly effective: standard treatment is 10,000 lux for ~30 min/day, and meta-analysis is described as showing ~70–80% response rates in well-selected patients.
  • For neonatal hyperbilirubinemia, phototherapy is described as first-line treatment using blue light in the 460–490 nm range; the review states that large randomized controlled trials and meta-analyses confirm efficacy and safety.
  • For wound healing, a meta-analysis is said to show significant benefits, with collagen formation effect size +2.78, plus improved healing rate and tensile strength.
  • For organ protection, the review highlights preclinical and preliminary human findings: in bacterial pneumonia models, 0% survival in mice lacking ATII-specific PER2 versus 85% survival in controls; in a preliminary human spine-surgery study, 30 min of sunrise light for 5 days increased plasma ANGPTL4 and decreased troponin versus historical controls/baseline.

## Methods

  • Narrative review/synthesis of current research on light therapy’s mechanisms, efficacy, safety, and clinical applications across multiple domains.
  • The paper distinguishes major modalities, including visual/photoneuromodulatory light therapy versus peripheral PBM and UV phototherapy, and discusses evidence separately by indication.
  • Evidence base appears to include meta-analyses, randomized controlled trials, pilot studies, preclinical animal experiments, and one preliminary human study; no systematic search strategy or pooled analysis is stated in the provided text.

## Limitations

  • The paper states that evidence for several uses is still limited: delirium evidence is from small trials, pain management evidence is often moderate or preliminary, and organ-protection applications are largely preclinical/mechanistic; this is explicitly stated in the text.
  • It also states that larger, more definitive, multi-center, or rigorous trials are needed for PMDD, TBI/PTSD sleep disturbance, substance use disorders, wound healing standardization, and long-term safety.
  • Evident from the text: the review is broad and heterogeneous, spanning many modalities and indications with different endpoints, which makes direct comparison difficult; the paper itself notes the need not to conflate modalities and evidence levels.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.21037/atm-2026-0041

Cites

0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Biomedical applications, mechanisms, and benefits of light therapy. Multiple wavelengths are relevant in light therapy, including blue light (415–450 nm), red light (630–700 nm), NIR, green, and UV light. Full-spectrum and intense light therapy are described by their intensity (e.g., 10,000 or 5,000 lux), which refers to illuminance rather than wavelength. Lux should not be presented as an equivalent category to wavelength, since it measures light intensity rather than spectral composition. Clinical applications should reflect this diversity: blue, red, NIR, green, and UV wavelengths are used for skin conditions, while full-spectrum and intense light are applied in mood and circadian disorders. The mechanisms presented should be interpreted with caution; while some disorders may involve mitochondrial or hormonal modulation, this is not established for all indications. The systemic effects of intense light exposure, including potential cardioprotective effects, remain under investigation and require further confirmation. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; NIR, near-infrared; UV, ultraviolet.
Figure 1 Biomedical applications, mechanisms, and benefits of light therapy. Multiple wavelengths are relevant in light therapy, including blue light (415–450 nm), red light (630–700 nm), NIR, green, and UV light. Full-spectrum and intense light therapy are described by their intensity (e.g., 10,000 or 5,000 lux), which refers to illuminance rather than wavelength. Lux should not be presented as an equivalent category to wavelength, since it measures light intensity rather than spectral composition. Clinical applications should reflect this diversity: blue, red, NIR, green, and UV wavelengths are used for skin conditions, while full-spectrum and intense light are applied in mood and circadian disorders. The mechanisms presented should be interpreted with caution; while some disorders may involve mitochondrial or hormonal modulation, this is not established for all indications. The systemic effects of intense light exposure, including potential cardioprotective effects, remain under investigation and require further confirmation. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; NIR, near-infrared; UV, ultraviolet.CC BY-NC-ND · PubMed Central
Figure 2 Mechanisms of light therapy. The current illustration focuses primarily on mitochondrial and circadian pathways, which represent only a subset of the mechanisms by which light therapy exerts its effects. Light therapy is known to modulate a broad range of biological pathways, including but not limited to mitochondrial activation, circadian regulation, melatonin synthesis, immune modulation, anti-inflammatory signaling, nitric oxide production, and opioid system activation (particularly with green light in pain management). Other pathways, such as modulation of cytokine networks, collagen synthesis, and neuroprotective signaling, are well described and have substantial supporting evidence. A more comprehensive depiction of the mechanisms is needed to avoid bias and better represent the field. Future revisions of the figure should incorporate these diverse, well-established mechanistic pathways and clarify that the selected mechanisms are not exhaustive or universally dominant across all forms of light therapy. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; ATP, adenosine triphosphate; ICU, intensive care unit; IR, ischemia-reperfusion; PER2, Period 2; SCN, suprachiasmatic nucleus.
Figure 2 Mechanisms of light therapy. The current illustration focuses primarily on mitochondrial and circadian pathways, which represent only a subset of the mechanisms by which light therapy exerts its effects. Light therapy is known to modulate a broad range of biological pathways, including but not limited to mitochondrial activation, circadian regulation, melatonin synthesis, immune modulation, anti-inflammatory signaling, nitric oxide production, and opioid system activation (particularly with green light in pain management). Other pathways, such as modulation of cytokine networks, collagen synthesis, and neuroprotective signaling, are well described and have substantial supporting evidence. A more comprehensive depiction of the mechanisms is needed to avoid bias and better represent the field. Future revisions of the figure should incorporate these diverse, well-established mechanistic pathways and clarify that the selected mechanisms are not exhaustive or universally dominant across all forms of light therapy. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; ATP, adenosine triphosphate; ICU, intensive care unit; IR, ischemia-reperfusion; PER2, Period 2; SCN, suprachiasmatic nucleus.CC BY-NC-ND · PubMed Central
Figure 3 Light, circadian rhythms, and metabolic health: pathways and clinical implications. Light signals detected by ipRGCs are transmitted to the SCN, synchronizing internal rhythms with the external light-dark cycle. Individual differences in light sensitivity, shaped by age, sex, chronotype, and genetics, modulate circadian responses. Proper daytime light exposure supports aligned sleep-wake patterns, hormonal rhythms (e.g., melatonin and cortisol), and metabolic homeostasis. In contrast, nighttime artificial light and circadian misalignment (e.g., shift work, irregular eating and sleeping) reduce melatonin, disrupt clock synchronization, and increase risk of obesity, metabolic syndrome, cardiovascular disease, and cancer. Clinical interventions such as structured light therapy, melatonin supplementation, and time-restricted eating aim to restore circadian alignment and improve cardiometabolic health. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; ipRGCs, intrinsically photosensitive retinal ganglion cells; PER2, Period 2; SCN, suprachiasmatic nucleus.
Figure 3 Light, circadian rhythms, and metabolic health: pathways and clinical implications. Light signals detected by ipRGCs are transmitted to the SCN, synchronizing internal rhythms with the external light-dark cycle. Individual differences in light sensitivity, shaped by age, sex, chronotype, and genetics, modulate circadian responses. Proper daytime light exposure supports aligned sleep-wake patterns, hormonal rhythms (e.g., melatonin and cortisol), and metabolic homeostasis. In contrast, nighttime artificial light and circadian misalignment (e.g., shift work, irregular eating and sleeping) reduce melatonin, disrupt clock synchronization, and increase risk of obesity, metabolic syndrome, cardiovascular disease, and cancer. Clinical interventions such as structured light therapy, melatonin supplementation, and time-restricted eating aim to restore circadian alignment and improve cardiometabolic health. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; ipRGCs, intrinsically photosensitive retinal ganglion cells; PER2, Period 2; SCN, suprachiasmatic nucleus.CC BY-NC-ND · PubMed Central
Figure 4 Therapeutic light modalities: LED, laser, and biological pathways. (A) LED therapy uses low-level red (≈650 nm) and blue (400–500 nm) light to enhance mitochondrial function, collagen synthesis, vascular dynamics, and antimicrobial responses, supporting wound healing and dermatological applications. (B) Laser therapy delivers coherent light (650 nm; near-infrared 800–1,100 nm) to stimulate ATP production and cellular signaling, enabling precise treatment of superficial and deep tissues, including oral mucositis and chronic injuries. (C) Light exposure regulates circadian rhythms and metabolism: daytime light stabilizes central and peripheral clocks, whereas nighttime artificial light suppresses melatonin, disrupts metabolic homeostasis, and increases cardiometabolic risk. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; ATP, adenosine triphosphate; CVD, cardiovascular disease; LED, light emitting diode; ROS, reactive oxygen species; SCN, suprachiasmatic nucleus; T2D, type 2 diabetes.
Figure 4 Therapeutic light modalities: LED, laser, and biological pathways. (A) LED therapy uses low-level red (≈650 nm) and blue (400–500 nm) light to enhance mitochondrial function, collagen synthesis, vascular dynamics, and antimicrobial responses, supporting wound healing and dermatological applications. (B) Laser therapy delivers coherent light (650 nm; near-infrared 800–1,100 nm) to stimulate ATP production and cellular signaling, enabling precise treatment of superficial and deep tissues, including oral mucositis and chronic injuries. (C) Light exposure regulates circadian rhythms and metabolism: daytime light stabilizes central and peripheral clocks, whereas nighttime artificial light suppresses melatonin, disrupts metabolic homeostasis, and increases cardiometabolic risk. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; ATP, adenosine triphosphate; CVD, cardiovascular disease; LED, light emitting diode; ROS, reactive oxygen species; SCN, suprachiasmatic nucleus; T2D, type 2 diabetes.CC BY-NC-ND · PubMed Central
Figure 5 Role of wavelengths in therapeutic outcomes. (A) Spectrum and tissue penetration: Blue light (400–500 nm) primarily acts at superficial skin layers with antimicrobial effects. Red light (~660 nm) penetrates into dermal and subcutaneous tissues, promoting cellular repair and ATP production. NIR (NIR-I: 700–900 nm; NIR-II: 900–1,100 nm) achieves the deepest tissue penetration, enabling effects in deep tissues and the central nervous system. The use of the term NIR-II (900–1,100 nm) here follows a convention adopted in some PBM and biomedical optics literature, though definitions vary, and other sources may define NIR-II as extending up to 1,700 nm. However, there is no universally accepted standard for NIR-II in the context of PBM. (B) Mechanisms of action by wavelength: blue light reduces microbial load and inflammation. Red light enhances mitochondrial activity, collagen synthesis, and microcirculation. NIR modulates cytochrome c oxidase activity and mitochondrial respiration, contributing to tissue repair and neuroprotection. (C) Synergy and wavelength combinations: dual- or multi-wavelength approaches (e.g., 660 nm + 810/850 nm) amplify ATP production and anti-inflammatory responses, often producing superior clinical outcomes compared to single wavelengths. (D) Immunomodulation and mechanistic precision: specific wavelengths influence macrophage polarization (M1 to M2), cytokine profiles, and brain network activity, highlighting wavelength-dependent biological targeting. (E) Key determinants of efficacy: therapeutic success depends on wavelength selection, photon fluence (the total number of photons delivered per unit area, typically measured in J/cm2), power density, and temporal distribution rather than intensity alone. (F) Future directions: standardization of protocols, investigation of wavelength combinations, personalized dosimetry, and deeper mechanistic understanding are essential for precision light therapy. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; ATP, adenosine triphosphate; LED, light emitting diode; NIR, near-infrared; PBM, photobiomodulation; ROS, reactive oxygen species.
Figure 5 Role of wavelengths in therapeutic outcomes. (A) Spectrum and tissue penetration: Blue light (400–500 nm) primarily acts at superficial skin layers with antimicrobial effects. Red light (~660 nm) penetrates into dermal and subcutaneous tissues, promoting cellular repair and ATP production. NIR (NIR-I: 700–900 nm; NIR-II: 900–1,100 nm) achieves the deepest tissue penetration, enabling effects in deep tissues and the central nervous system. The use of the term NIR-II (900–1,100 nm) here follows a convention adopted in some PBM and biomedical optics literature, though definitions vary, and other sources may define NIR-II as extending up to 1,700 nm. However, there is no universally accepted standard for NIR-II in the context of PBM. (B) Mechanisms of action by wavelength: blue light reduces microbial load and inflammation. Red light enhances mitochondrial activity, collagen synthesis, and microcirculation. NIR modulates cytochrome c oxidase activity and mitochondrial respiration, contributing to tissue repair and neuroprotection. (C) Synergy and wavelength combinations: dual- or multi-wavelength approaches (e.g., 660 nm + 810/850 nm) amplify ATP production and anti-inflammatory responses, often producing superior clinical outcomes compared to single wavelengths. (D) Immunomodulation and mechanistic precision: specific wavelengths influence macrophage polarization (M1 to M2), cytokine profiles, and brain network activity, highlighting wavelength-dependent biological targeting. (E) Key determinants of efficacy: therapeutic success depends on wavelength selection, photon fluence (the total number of photons delivered per unit area, typically measured in J/cm2), power density, and temporal distribution rather than intensity alone. (F) Future directions: standardization of protocols, investigation of wavelength combinations, personalized dosimetry, and deeper mechanistic understanding are essential for precision light therapy. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; ATP, adenosine triphosphate; LED, light emitting diode; NIR, near-infrared; PBM, photobiomodulation; ROS, reactive oxygen species.CC BY-NC-ND · PubMed Central
Figure 6 Safety and side effects of therapeutic light exposure. (A) Types of light therapy and main uses: common modalities include bright white light (e.g., for seasonal affective disorder), red and blue light devices for dermatological and ophthalmic applications, near-infrared devices for transcranial photobiomodulation, and UV-C lamps for germicidal use (hazardous to humans). (B) Side effects by wavelength: bright, red, blue, and near-infrared light therapies are generally associated with mild and transient side effects (e.g., headache, eye strain, skin irritation, temporary afterimages). In contrast, UV-C exposure may cause severe and irreversible cellular damage to skin and retinal tissue. (C) Mechanism and Risk modifiers: safety depends on wavelength, intensity, exposure duration, and individual patient factors (e.g., age, ocular disease, medications). Appropriate parameter selection optimizes benefit-risk balance. (D) Safety optimization and recommendations: standardized protocols (e.g., 10,000 lux for 30–60 min in the morning), ophthalmologic screening in at-risk individuals, avoidance of UV-C exposure, personalization of therapy, and monitoring during long-term use improve safety. (E) Gaps and future directions: further research is needed to establish long-term safety and standardized guidelines, particularly for emerging applications and vulnerable populations. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; UV, ultraviolet.
Figure 6 Safety and side effects of therapeutic light exposure. (A) Types of light therapy and main uses: common modalities include bright white light (e.g., for seasonal affective disorder), red and blue light devices for dermatological and ophthalmic applications, near-infrared devices for transcranial photobiomodulation, and UV-C lamps for germicidal use (hazardous to humans). (B) Side effects by wavelength: bright, red, blue, and near-infrared light therapies are generally associated with mild and transient side effects (e.g., headache, eye strain, skin irritation, temporary afterimages). In contrast, UV-C exposure may cause severe and irreversible cellular damage to skin and retinal tissue. (C) Mechanism and Risk modifiers: safety depends on wavelength, intensity, exposure duration, and individual patient factors (e.g., age, ocular disease, medications). Appropriate parameter selection optimizes benefit-risk balance. (D) Safety optimization and recommendations: standardized protocols (e.g., 10,000 lux for 30–60 min in the morning), ophthalmologic screening in at-risk individuals, avoidance of UV-C exposure, personalization of therapy, and monitoring during long-term use improve safety. (E) Gaps and future directions: further research is needed to establish long-term safety and standardized guidelines, particularly for emerging applications and vulnerable populations. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; UV, ultraviolet.CC BY-NC-ND · PubMed Central
Figure 7 Impact of indoor light attenuation on patient circadian health. The schematic illustrates the drastic reduction in natural light intensity (lux) from the outside environment to a hospital patient bed, highlighting how factors like window glass, room depth, and shading limit biological light exposure. The inset graph contrasts actual light levels at the bed (500 lux) against the minimum requirement for circadian regulation (1,200 lux) and therapeutic boost phases (2,000 lux). Prolonged light deficiency is linked to fatigue, poor concentration, and sleep disorders, underscoring the clinical need for coordinated artificial lighting systems. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence.
Figure 7 Impact of indoor light attenuation on patient circadian health. The schematic illustrates the drastic reduction in natural light intensity (lux) from the outside environment to a hospital patient bed, highlighting how factors like window glass, room depth, and shading limit biological light exposure. The inset graph contrasts actual light levels at the bed (500 lux) against the minimum requirement for circadian regulation (1,200 lux) and therapeutic boost phases (2,000 lux). Prolonged light deficiency is linked to fatigue, poor concentration, and sleep disorders, underscoring the clinical need for coordinated artificial lighting systems. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence.CC BY-NC-ND · PubMed Central
Figure 8 Light therapy applications in mental health and substance use disorders. Environmental factors such as artificial light at night and chronic jet lag disrupt circadian rhythms and clock gene expression, contributing to neurotransmitter imbalance, impaired neural circuitry, and metabolic dysfunction. Circadian rhythm dysfunction is bidirectionally linked to SUDs, influencing reward circuitry and addiction behaviors. Light-based interventions, including chronotherapy and structured light exposure management, aim to restore circadian alignment and potentially normalize reward-related pathways. While light therapy shows promise as an adjunctive strategy in SUDs, current evidence remains limited. Established treatments with stronger empirical support include transcranial magnetic stimulation, cognitive behavioral therapy, and pharmacological approaches. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; SUDs, substance use disorders.
Figure 8 Light therapy applications in mental health and substance use disorders. Environmental factors such as artificial light at night and chronic jet lag disrupt circadian rhythms and clock gene expression, contributing to neurotransmitter imbalance, impaired neural circuitry, and metabolic dysfunction. Circadian rhythm dysfunction is bidirectionally linked to SUDs, influencing reward circuitry and addiction behaviors. Light-based interventions, including chronotherapy and structured light exposure management, aim to restore circadian alignment and potentially normalize reward-related pathways. While light therapy shows promise as an adjunctive strategy in SUDs, current evidence remains limited. Established treatments with stronger empirical support include transcranial magnetic stimulation, cognitive behavioral therapy, and pharmacological approaches. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; SUDs, substance use disorders.CC BY-NC-ND · PubMed Central
Figure 9 Wavelength-specific mechanisms of light-mediated pain modulation. 1: red and near-infrared light enhance mitochondrial ATP production and activate anti-inflammatory signaling pathways. 2: green and red light differentially modulate neuronal subpopulations within pain-processing circuits such as the vLGN. Green light preferentially activates glutamatergic neurons and induces antinociception, whereas red light can enhance nociceptive signaling via GABAergic pathways. Although green light has demonstrated analgesic effects, its direct impact on mitochondrial function remains unclear and not well established in the literature; most current evidence suggests that green light primarily acts through central nervous system pathways, such as opioid system activation, rather than through mitochondrial modulation. 3: opioid system activation: green light stimulates endogenous opioid release (β-endorphin, proenkephalin) and engages μ- and δ-opioid receptors, contributing to analgesic effects without exogenous opioid administration. 4: PBM also reduces inflammatory mediators (e.g., COX-2, IL-6) and modulates peripheral and central nociceptive pathways. 5-7: therapeutic efficacy depends on wavelength, irradiance, fluence, and exposure route (cutaneous vs. visual). Applications include dental pain, temporomandibular disorders, neuropathic pain, migraine, fibromyalgia, and multimodal analgesia. Emerging approaches integrate personalized dosimetry and photopharmacology to enhance precision in pain management. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; ATP, adenosine triphosphate; IL-6, interleukin 6; LED, light emitting diode; PBM, photobiomodulation; PER2, Period 2; vLGN, ventral lateral geniculate nucleus;
Figure 9 Wavelength-specific mechanisms of light-mediated pain modulation. 1: red and near-infrared light enhance mitochondrial ATP production and activate anti-inflammatory signaling pathways. 2: green and red light differentially modulate neuronal subpopulations within pain-processing circuits such as the vLGN. Green light preferentially activates glutamatergic neurons and induces antinociception, whereas red light can enhance nociceptive signaling via GABAergic pathways. Although green light has demonstrated analgesic effects, its direct impact on mitochondrial function remains unclear and not well established in the literature; most current evidence suggests that green light primarily acts through central nervous system pathways, such as opioid system activation, rather than through mitochondrial modulation. 3: opioid system activation: green light stimulates endogenous opioid release (β-endorphin, proenkephalin) and engages μ- and δ-opioid receptors, contributing to analgesic effects without exogenous opioid administration. 4: PBM also reduces inflammatory mediators (e.g., COX-2, IL-6) and modulates peripheral and central nociceptive pathways. 5-7: therapeutic efficacy depends on wavelength, irradiance, fluence, and exposure route (cutaneous vs. visual). Applications include dental pain, temporomandibular disorders, neuropathic pain, migraine, fibromyalgia, and multimodal analgesia. Emerging approaches integrate personalized dosimetry and photopharmacology to enhance precision in pain management. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; ATP, adenosine triphosphate; IL-6, interleukin 6; LED, light emitting diode; PBM, photobiomodulation; PER2, Period 2; vLGN, ventral lateral geniculate nucleus;CC BY-NC-ND · PubMed Central
Figure 10 Intense light therapy enhances circadian amplitude for multisystem organ protection. Intense light exposure (e.g., 10,000 lux, extended light-dark cycles) increases circadian amplitude, particularly through upregulation of PER2 within the molecular clock network (PER/CRY/CLOCK/BMAL1). Enhanced circadian oscillations optimize gene expression programs involved in metabolism, innate immunity, and stress resilience. This amplification of circadian signaling improves organ protection against infection, ischemia, and hemorrhagic shock in lung, heart, and kidney. In contrast, circadian disruption (e.g., shift work, irregular light exposure) reduces resilience and increases susceptibility to inflammatory, metabolic, and cardiovascular disease. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; PER2, Period 2.
Figure 10 Intense light therapy enhances circadian amplitude for multisystem organ protection. Intense light exposure (e.g., 10,000 lux, extended light-dark cycles) increases circadian amplitude, particularly through upregulation of PER2 within the molecular clock network (PER/CRY/CLOCK/BMAL1). Enhanced circadian oscillations optimize gene expression programs involved in metabolism, innate immunity, and stress resilience. This amplification of circadian signaling improves organ protection against infection, ischemia, and hemorrhagic shock in lung, heart, and kidney. In contrast, circadian disruption (e.g., shift work, irregular light exposure) reduces resilience and increases susceptibility to inflammatory, metabolic, and cardiovascular disease. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; PER2, Period 2.CC BY-NC-ND · PubMed Central
Figure 11 Cell-type-specific roles of PER2 in lung protection: using a conditional knockout approach employing genetic deletion of Per2 in specific lung cell populations, researchers compared mice with Per2 deletion in ATII cells, endothelial cells, or myeloid cells. These experiments demonstrated that PER2 in ATII cells is essential for survival in Pseudomonas aeruginosa-induced ALI, whereas deletion in endothelial or myeloid cells does not abolish protection. Intense light exposure or pharmacologic PER2 enhancement (nobiletin) increases circadian amplitude and upregulates BPIFB1 in ATII cells, promoting antibacterial defense, reducing inflammation, and preserving alveolar barrier integrity. Loss of ATII-specific PER2 eliminates these protective effects, highlighting a cell-type-specific circadian mechanism of lung resilience with potential clinical relevance in populations with circadian disruption. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; ALI, acute lung injury; ATII, alveolar type II; BPIFB1, bactericidal/permeability-increasing fold-containing family B member 1; ICU, intensive care unit; KO, knockdown; LPS, lipopolysaccharide; PER2, Period 2; WT, wild-type.
Figure 11 Cell-type-specific roles of PER2 in lung protection: using a conditional knockout approach employing genetic deletion of Per2 in specific lung cell populations, researchers compared mice with Per2 deletion in ATII cells, endothelial cells, or myeloid cells. These experiments demonstrated that PER2 in ATII cells is essential for survival in Pseudomonas aeruginosa-induced ALI, whereas deletion in endothelial or myeloid cells does not abolish protection. Intense light exposure or pharmacologic PER2 enhancement (nobiletin) increases circadian amplitude and upregulates BPIFB1 in ATII cells, promoting antibacterial defense, reducing inflammation, and preserving alveolar barrier integrity. Loss of ATII-specific PER2 eliminates these protective effects, highlighting a cell-type-specific circadian mechanism of lung resilience with potential clinical relevance in populations with circadian disruption. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; ALI, acute lung injury; ATII, alveolar type II; BPIFB1, bactericidal/permeability-increasing fold-containing family B member 1; ICU, intensive care unit; KO, knockdown; LPS, lipopolysaccharide; PER2, Period 2; WT, wild-type.CC BY-NC-ND · PubMed Central
Figure 12 Mechanism and clinical potential of intense light therapy in ischemia-reperfusion and hemorrhagic shock injury. Coronary artery occlusion induces myocardial ischemia. Upon reperfusion, a burst of ROS, calcium overload, and inflammatory cell activation leads to endothelial and myocardial injury, contributing substantially to infarct size. Intense light exposure enhances PER2 expression and activates the PER2/HIF1A/ANGPTL4 pathway, promoting endothelial barrier integrity and limiting oxidative stress, inflammation, and calcium overload during myocardial ischemia-reperfusion injury. ANGPTL4 preserves tight junctions, reduces vascular leakage, and attenuates myocardial damage. In surgical patients, perioperative intense light increased plasma ANGPTL4 and reduced troponin levels, suggesting decreased myocardial injury (MINS). In murine hemorrhagic shock models, light pretreatment improved hemodynamic stability and reduced inflammatory markers with translational anti-inflammatory effects observed in human plasma proteomics. Collectively, these findings support intense light therapy as a potential circadian-based adjunct for organ protection in perioperative and critical care settings. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; ANGPTL4, angiopoietin-like 4; HIF1A, hypoxia-inducible factor 1 alpha; IL-6, interleukin 6; IL-8, interleukin 8; IR, ischemia-reperfusion; MAP, mean arterial pressure; MINS, myocardial injury in non-cardiac surgery; PER2, Period 2; ROS, reactive oxygen species.
Figure 12 Mechanism and clinical potential of intense light therapy in ischemia-reperfusion and hemorrhagic shock injury. Coronary artery occlusion induces myocardial ischemia. Upon reperfusion, a burst of ROS, calcium overload, and inflammatory cell activation leads to endothelial and myocardial injury, contributing substantially to infarct size. Intense light exposure enhances PER2 expression and activates the PER2/HIF1A/ANGPTL4 pathway, promoting endothelial barrier integrity and limiting oxidative stress, inflammation, and calcium overload during myocardial ischemia-reperfusion injury. ANGPTL4 preserves tight junctions, reduces vascular leakage, and attenuates myocardial damage. In surgical patients, perioperative intense light increased plasma ANGPTL4 and reduced troponin levels, suggesting decreased myocardial injury (MINS). In murine hemorrhagic shock models, light pretreatment improved hemodynamic stability and reduced inflammatory markers with translational anti-inflammatory effects observed in human plasma proteomics. Collectively, these findings support intense light therapy as a potential circadian-based adjunct for organ protection in perioperative and critical care settings. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. AI, artificial intelligence; ANGPTL4, angiopoietin-like 4; HIF1A, hypoxia-inducible factor 1 alpha; IL-6, interleukin 6; IL-8, interleukin 8; IR, ischemia-reperfusion; MAP, mean arterial pressure; MINS, myocardial injury in non-cardiac surgery; PER2, Period 2; ROS, reactive oxygen species.CC BY-NC-ND · PubMed Central
Figure 13 Intense light therapy in circadian regulation of blood coagulation. Platelet reactivity and coagulation factors exhibit pronounced early-morning peaks, coinciding with increased thrombotic risk. PER2 acts as a negative regulator of platelet activation and TF-mediated coagulation. Genetic deletion of Per2 in megakaryocytes accelerates aggregation and shortens clotting time, supporting its antithrombotic role. Intense light exposure enhances PER2 expression in platelets and endothelium, reduces platelet aggregation, suppresses TF activity, and increases anticoagulant pathways (thrombomodulin, EPCR, TFPI, protein C/S) while preserving primary hemostasis. Light-enhanced PER2 also improves endothelial barrier integrity and nitric oxide signaling. Morning-timed light therapy flattens circadian variation in prothrombotic factors, reducing peak thrombotic risk. Clinical translation supports early-morning light exposure as a potential non-pharmacological strategy to lower thrombosis risk without increasing bleeding complications. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. EPCR, endothelial protein C receptor; NO, nitric oxide; PER2, Period 2; SCN, suprachiasmatic nucleus; TF, tissue factor; TFPI, tissue factor pathway inhibitor.
Figure 13 Intense light therapy in circadian regulation of blood coagulation. Platelet reactivity and coagulation factors exhibit pronounced early-morning peaks, coinciding with increased thrombotic risk. PER2 acts as a negative regulator of platelet activation and TF-mediated coagulation. Genetic deletion of Per2 in megakaryocytes accelerates aggregation and shortens clotting time, supporting its antithrombotic role. Intense light exposure enhances PER2 expression in platelets and endothelium, reduces platelet aggregation, suppresses TF activity, and increases anticoagulant pathways (thrombomodulin, EPCR, TFPI, protein C/S) while preserving primary hemostasis. Light-enhanced PER2 also improves endothelial barrier integrity and nitric oxide signaling. Morning-timed light therapy flattens circadian variation in prothrombotic factors, reducing peak thrombotic risk. Clinical translation supports early-morning light exposure as a potential non-pharmacological strategy to lower thrombosis risk without increasing bleeding complications. This illustration was generated via the FigureLabs AI-assisted scientific illustration platform and subsequently edited in Inkscape. EPCR, endothelial protein C receptor; NO, nitric oxide; PER2, Period 2; SCN, suprachiasmatic nucleus; TF, tissue factor; TFPI, tissue factor pathway inhibitor.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

0 Valid · 13 Not valid · 207 Not checked · 70 Own results and interpretations

154 more claims

Create a free account to see all 290 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 122
  • Probably not a substantial claim. 16

Create a free account to see these claims.

Citations

Cites

The publisher hasn’t deposited this paper’s reference list.

Research works printed but not linked: 2

  1. [47]Doskaliuk B. Phototherapy: cutaneous and systemic rejuvenation. Anti-Aging Eastern Europe 2025; 4: 108- 11.
  2. [122]Chung EH Son JW Eun YS A Novel, Hand-Held, and Low-Level Light Therapy Device for the Treatment of Acne Vulgaris: A Single-Arm, Prospective Clinical Study. Dermatol Ther 2023; 2023: 8846620.

Metadata

Authors
Oyama, Y., Witowski, A., Adamzik, M., Bartels, K., & de la Garza Eckle, T.
Affiliations
  • Oita University (JP)
  • University Hospitals of the Ruhr-University of Bochum (DE)
  • University of Michigan (US)
Venue
Annals of Translational Medicine
Published
2026-06
Volume
14
Issue
3
Pages
35-35
ISSN
  • 2305-5839 (ISSN-L)
  • 2305-5847
OpenAlex
W7166669340
Cited by
0
References
0
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Annals of Translational Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
Funders
National Heart, Lung, and Blood Institute (R56HL156955, R01HL122472)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Laser Applications in Dentistry and Medicine
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Complementary and alternative medicine › Biofield Effects and Biophysics
Keywords
phototherapy, low-level laser therapy, bright light therapy, circadian rhythm, seasonal affective disorder, ultraviolet therapy, psoriasis, mitochondrial activation, Per2, delirium, pain management, ischemia-reperfusion injury, clotting disorders, lung injury, evidence hierarchy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Light therapy in medicine: where do we stand? https://app.cochat.ai/papers/10.21037/atm-2026-0041
The paper
Oyama, Y., Witowski, A., Adamzik, M., Bartels, K., & de la Garza Eckle, T. (2026). Light therapy in medicine: where do we stand? Annals of Translational Medicine. https://doi.org/10.21037/atm-2026-0041

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.